Staphylococcus aureus vesicle encapsulated endoplasmic reticulum targeting nanoparticles and application thereof
The endoplasmic reticulum targets nanoparticles through the Staphylococcus aureus membrane vesicles, and combines photosensitizers modified by PLGA and DSPE-PEG to target the endoplasmic reticulum of tumor cells, solving the deficiency of immunogenicity and immunosuppression of photodynamic therapy. The problem has achieved the effect of enhancing immune response and anti-tumor efficacy.
Patent Information
- Application Number
- CN202411092687.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
Photodynamic therapy is insufficient immunogenicity and immunosuppressive microenvironment in anti-tumor treatment limit its efficacy. The construction of existing drug-loading systems is difficult to accurately adjust and can easily cause photosensitizer inactivation, and the toxic components of Gram-negative bacterial membrane vesicles. Limits its application.
The endoplasmic reticulum targeted nanoparticles were encapsulated by Staphylococcus aureus membrane bubbles, and the MVs@PLGA/TSE-PPA nanoparticles were formed by encapsulating pyrodemagnesium chlorochloric acid-a modified by PLGA and DSPE-PEG nanomaterials. Toward the endoplasmic reticulum of tumor cells, enhance ROS-induced endoplasmic reticulum stress and immune response.
Effectively reverse the immunosuppressive microenvironment, enhance T cell proliferation and immunogenic death in the tumor microenvironment, coordinately enhance the effect of cancer immunotherapy, and improve anti-tumor efficacy and biosafety.
Smart Images

Figure HDA0004987023240000011 
Figure HDA0004987023240000021 
Figure HDA0004987023240000031
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a Staphylococcus aureus membrane vesicle-encapsulated endoplasmic reticulum-targeted nanoparticle and an application thereof. Background Art
[0002] The development of immunotherapy in recent years has revolutionized the treatment of cancer and achieved significant clinical therapeutic effects in certain types of cancer. Photodynamic therapy (PDT) can specifically kill tumors and induce immunogenic death of tumor cells, making it a promising anti-tumor treatment. However, insufficient immunogenicity and immunosuppressive microenvironment limit its immunotherapeutic efficacy. Therefore, different approaches are needed to enhance the immune response of PDT.
[0003] The main reason for immunogenic death (ICD) caused by photodynamic therapy is that ROS generated by laser irradiation can induce endoplasmic reticulum stress, leading to calreticulin (CRT) exposure and danger-associated molecular patterns (DAMPs) release. Therefore, ROS-induced endoplasmic reticulum stress determines the efficacy of PDT-mediated ICD. However, 1 The shorter half-life of O2 (10-320ns) reduces the accumulation of ROS in the ER, thereby limiting the induction of ER stress. Therefore, targeting photosensitizers to the ER and generating ROS in the ER can enhance ROS-induced ER stress, thereby enhancing tumor autoimmunogenicity. Among them, the photosensitizer pyropheophorbide-a (PPA) is modified with the ER-targeted small molecule ligand N-toluenesulfonylethylenediamine (TSE), whose cyclohexylsulfonylurea group has a high affinity for the ATP-sensitive K+ channel (sulfonylurea receptor) protruding on the ER membrane. PLGA and DSPE-PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol) nanomaterials are coated to construct ER-targeted nanoparticles to enhance immunogenic death.
[0004] In addition, regulating the immunosuppressive tumor microenvironment is another key to improving photodynamic immunotherapy. The combined strategy of photodynamic therapy and regulating the immunosuppressive microenvironment has been partially studied, such as the combination with the toll-like receptor (TLR) agonist imiquimod, inhibitory molecules (such as TGF-β inhibitors, indoleamine 2,3-dioxygenase inhibitors) or STING agonists. However, in order to achieve better therapeutic effects, it is necessary to accurately adjust the type and amount of drug loading and avoid interactions between co-loaded drugs, such as easily causing photosensitizer inactivation, which brings extremely difficult tasks to the construction of drug delivery systems.
[0005] The application of natural materials with immunostimulatory functions is expected to overcome the above challenges. Bacterial membrane vesicles (BMVs) are nanoscale spherical double-layer membrane structures with a variety of endogenous immunostimulatory components. Gram-negative bacterial vesicles called outer membrane vesicles (OMVs) have been widely described. However, their application is limited by toxic components such as lipopolysaccharide in OMVs. In 2009, Korean scientists first discovered the ability of the Gram-positive bacterium Staphylococcus aureus to produce membrane vesicles (MVs). The lipid bile acid (TLR2), peptidoglycan (NOD2), RNA (TLR7 and 8) and DNA (TLR9) carried by Staphylococcus aureus can be recognized by innate immune receptors NOD2 and TLR2 / 7 / 8 / 9, thereby stimulating innate immune receptors and activating innate immune responses. More importantly, Gram-positive bacteria themselves do not contain toxic components such as lipopolysaccharide, and are theoretically safer. In view of the good immunostimulatory effect of Staphylococcus aureus membrane vesicles, the inventors attempted to use Staphylococcus aureus membrane vesicles as an immune adjuvant to effectively reverse the immunosuppressive microenvironment, thereby amplifying the immune response and enhancing the anti-tumor efficacy, thereby completing the present invention. Summary of the invention
[0006] The purpose of the present invention is to provide a Staphylococcus aureus membrane vesicle encapsulated endoplasmic reticulum targeting nanoparticle (MVs@PLGA / TSE-PPA) and its application. The nanoparticle can target the endoplasmic reticulum of tumor cells. After reaching the tumor tissue, the bacterial membrane vesicle acts as an immune adjuvant to increase the proliferation of effector T cells in the tumor microenvironment, while TSE-PPA endoplasmic reticulum targeted photodynamic therapy enhances the immunogenic death of tumor cells, thereby synergistically enhancing the cellular immune response and enhancing cancer immunotherapy.
[0007] To achieve the purpose of the present invention, the following technical solutions are provided.
[0008] In one embodiment of the present invention, a Staphylococcus aureus membrane vesicle encapsulated endoplasmic reticulum targeting nanoparticle comprises Staphylococcus aureus membrane vesicle (MVs), PLGA, DSPE-PEG2000 and N-tosylethylenediamine (TSE)-modified pyropheophorbide-a (PPA) (TSE-PPA), wherein the TSE-PPA forms nanoparticles with PLGA and DSPE-PEG2000, and the nanoparticles are then encapsulated in MVs to form MVs@PLGA / TSE-PPA nanoparticles.
[0009] Preferably, in the nanoparticles of the present invention, the mass ratio of TSE-PPA, TSE to PPA is 3:5; the mass ratio of PLGA to TSE-PPA is 25:3; and the mass ratio of PLGA to DSPE-PEG2000 is 2:1.
[0010] In another embodiment, the present invention also provides a method for preparing Staphylococcus aureus membrane vesicle-encapsulated endoplasmic reticulum-targeted nanoparticles, comprising the following steps:
[0011] 1) Dissolve TSE and PPA in dichloromethane, add catalyst EDC, HOBt and triethylamine to react and generate TSE-PPA;
[0012] 2) dissolving PLGA and DSPE-PEG2000 in DMSO, adding TSE-PPA DMSO solution, mixing, stirring, and slowly adding deionized water dropwise to obtain PLGA / TSE-PPA nanoparticle solution;
[0013] 3) The PLGA / TSE-PPA nanoparticle solution obtained in the previous step is ultrasonically mixed with MVs to obtain MVs@PLGA / TSE-PPA nanoparticles.
[0014] Preferably, in the preparation method of the present invention, step 1) further comprises washing the generated TSE-PPA solution with deionized water containing NaCl, and purifying the organic layer by column chromatography and evaporating to obtain TSE-PPA.
[0015] In the preparation method of the present invention, in step 1), the mobile phase of the column chromatography purification is a mixture of dichloromethane:ethyl acetate=2:1.
[0016] In the preparation method of the present invention, in step 1), the mass volume ratio of EDC, HOBt and triethylamine is 144 mg:101 mg:30 μL, wherein the mass ratio of PPA to HOBt is (1.9-2.0):1.
[0017] In the preparation method of the present invention, in step 2), the DMSO solution of TSE-PPA has a TSE-PPA concentration of 20 mg / mL.
[0018] In the preparation method of the present invention, the Staphylococcus aureus membrane vesicles MVs in step 3) are prepared by the following method, which comprises:
[0019] a. Resuscitate the attenuated Staphylococcus aureus RN4220Δagr for 24 hours, select a single colony, shake culture it in TSB medium at 37°C and 200 rpm overnight, transfer it to 1L TSB liquid medium at a ratio of 1:100, shake culture it at 37°C and 200 rpm for 20 hours, and obtain a bacterial culture medium;
[0020] b. Take the bacterial culture medium, centrifuge it at 4°C for 20-30 minutes, collect the supernatant, filter it with a 0.45μm filter membrane to remove bacteria and bacterial debris, and use an ultrafiltration system with a molecular weight cutoff of 100kDa to concentrate the filtrate by about 60 times. Filter the concentrate with a 0.22μm filter, centrifuge the filtrate at 200000g at 4°C for 3 hours, and take the precipitate;
[0021] c. Wash the precipitate twice with sterile PBS, resuspend the precipitate in 4.4 mL of 50% Optiprep buffer, transfer it to an ultrafiltration tube, carefully add 4 mL of 40% and 1.6 mL of 10% Optiprep gradient buffer to the upper layer of the ultrafiltration tube, centrifuge horizontally at 200,000 g for 3 h at 4°C, collect the protein between the 40% and 10% interfaces, dissolve it in PBS, and store it at -80°C to obtain MVs;
[0022] The preparation of Optiprep buffer is as follows: 0.238 g of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) and 0.8775 g of NaCl are dissolved in 100 mL of ddH2O, the pH is adjusted to 7.0 with NaOH, and the solution is filtered through a 0.22 um filter.
[0023] In a specific embodiment, the preparation method of the above-mentioned Staphylococcus aureus membrane vesicle MVs comprises: resuscitating the attenuated Staphylococcus aureus RN4220Δagr strain on a TSB solid plate for 24 hours, selecting a single colony in 10mL TSB medium and shaking and culturing it overnight at 37°C and 200rpm, and then transferring it to 1L TSB liquid medium at a ratio of 1:100, and shaking and culturing it at 37°C and 200rpm for 20 hours. After the culture is completed, take 4000g of bacterial culture medium, centrifuge it at 4°C for 20-30min, collect the supernatant, and filter it with a 0.45μm filter membrane to remove bacteria and bacterial debris. The filtrate is concentrated by about 60 times with an ultrafiltration system with a molecular weight cutoff of 100kDa. The concentrate is filtered with a 0.22μm filter to remove any possible bacterial debris; the filtrate is centrifuged at 200000g for 3h at 4°C, and the precipitate is washed twice with sterile PBS. The precipitate was resuspended in 4.4 mL of 50% Optiprep buffer and transferred to an ultrafiltration tube. 4 mL of 40% and 1.6 mL of 10% Optiprep gradient buffer were carefully added to the upper layer of the ultrafiltration tube. The mixture was centrifuged horizontally at 200000 g for 3 h at 4°C. The protein between the 40% and 10% interfaces was collected and dissolved in PBS. MVs were obtained by storing at -80°C. Optiprep buffer was prepared by dissolving 0.238 g of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) and 0.8775 g of NaCl in 100 mL of ddH2O, adjusting the pH to 7.0 with NaOH, filtering with a 0.22 um filter, and storing at room temperature.
[0024] In another embodiment, the Staphylococcus aureus vesicle-encapsulated endoplasmic reticulum-targeted nanoparticles of the present invention are used for treating tumors, or for preparing drugs or agents for treating tumors.
[0025] The Staphylococcus aureus membrane vesicles of the present invention encapsulate endoplasmic reticulum targeting nanoparticles and have good biosafety. At the same time, given that the Staphylococcus aureus membrane vesicles have good immunostimulatory effects, as an immune adjuvant, they effectively reverse the immunosuppressive microenvironment, thereby amplifying the immune response and enhancing the anti-tumor efficacy, and TSE-PPA, as a photosensitizer, acts on the endoplasmic reticulum, not only can specifically kill tumors, but also induce immunogenic death of tumor cells, and synergistically interact with the Staphylococcus aureus membrane vesicles to improve the tumor microenvironment, thereby enhancing cancer immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Figure 4 is the anti-tumor efficacy and biosafety of MVs, where A is the experimental scheme of the anti-tumor effect of 4T1 tumor-bearing mice; B is the photo of 4T1 tumor-bearing mice after treatment; C is the curve of tumor volume change of mice after treatment with PBS and different concentrations of MVs; D is the tumor weight of mice at the end of the experiment; E is the spleen weight of mice at the end of the experiment; F is the body weight of mice during treatment; GI is the analysis of serum pro-inflammatory factors (IL-6, TNA-α and IFN-γ) levels; JO is the analysis of blood biochemical indicators (UREA, CREA, ALT, AST, CK, LDH) of tumor-bearing mice after treatment with MVs.
[0027] Figure 2 The figure is the characterization of MPTP nanoparticles, wherein A is a schematic diagram of MPTP preparation; B is a TEM image of PTP and MPTP nanoparticles; C is the particle size distribution of PTP and MPTP nanoparticles; D is the change of Zeta potential of PTP and MPTP nanoparticles in PBS (pH 7.4) at different time points; E is the change of particle size of PTP and MPTP nanoparticles in PBS (pH 7.4) at different time points; F is the composition of surface proteins of nanoparticles analyzed by SDS-PAGE; G is a confocal image of DIO-labeled MPTP nanoparticles; H is the ultraviolet absorption spectrum of MPTP nanoparticles; I is the ultraviolet absorption spectrum of a mixture of DPBF and MPTP nanoparticles under laser irradiation; J is the ratio of ultraviolet absorption to maximum absorbance at 420 nm of a mixture of DPBF and MPTP nanoparticles at different time points.
[0028] Figure 3Figure 3 is a diagram of the endoplasmic reticulum targeting ability of MPTP nanoparticles and the effect of inducing ROS production, wherein A is a confocal image of 4T1 cells after treatment with PTP and MPTP nanoparticles, showing the ER co-localization of PPA and TSE-PPA; BC are linear scanning fluorescence intensity spectra showing the ER co-localization of PPA and TSE-PPA nanoparticles; D is a confocal image of ROS expression in 4T1 cells after treatment with different treatment groups; EF are the average fluorescence intensities of ROS expression in 4T1 cells after treatment with different treatment groups detected by flow cytometry.
[0029] Figure 4 The figure shows the effect of MPTP nanoparticles inducing immunogenic death of 4T1 cells, where AB are the confocal images of CRT and HMGB1 expression in 4T1 cells after treatment with different treatment groups; CD are the average fluorescence intensities of CRT and HMGB1 expression in 4T1 cells after treatment with different treatment groups; E is the enzyme-linked immunosorbent assay result of HMGB1 in 4T1 cells after treatment with different treatment groups; F is the ATP secretion of 4T1 cells after treatment with different treatment groups measured by ATP assay kit; GH is the stimulation of DC cell maturation by tumor cells after treatment with different treatment groups.
[0030] Figure 5 The figure is a diagram of the in vivo anti-tumor effect of MPTP nanoparticles, where A is the experimental scheme of the anti-tumor effect on 4T1 tumor-bearing mice; B is the tumor growth curve of mice after treatment with PBS, PP+, PTP+, MPTP+, and MPTP; C is the tumor weight of mice at the end of the experiment; D is the weight change curve of mice after treatment with PBS, PP+, PTP+, MPTP+, and MPTP; E is the H&E staining of tumor tissue, CRT exposure, and HMGB1 release in tumor sections.
[0031] Figure 6 The figure is the effect diagram of MPTP nanoparticles inducing immune response in vivo, where A and B are the proportions of mature DC cells in lymph nodes after treatment; C and E are the proportions of CD8 + T cell infiltration; D and F are CD4 + T cell infiltration; G is IFN-γ in the tumor after treatment + CD8 + T cell infiltration; H is intratumoral TNF-α + CD8 + T cell infiltration; I is tissue section to examine CD4 + T cells and CD8 + T cells.
[0032] Figure 7The figure is a diagram of the anti-pulmonary metastasis effect of MPTP nanoparticles in vivo, where A is the in vivo anti-pulmonary metastasis experimental scheme; B is a picture of lung tissue; C is a microscope image of lung tissue after H&E staining, scale: 250μm; D is the weight of lung tissue; E is the lung metastasis inhibition rate of mice after treatment with PBS, PP+laser, PTP+laser, MPTP+laser, and MPTP; F is the weight change curve of mice after treatment with PBS, PP+laser, PTP+laser, MPTP+laser, and MPTP. DETAILED DESCRIPTION
[0033] The following examples are representative and are used to further understand and illustrate the essence of the present invention. Any simple modification and adaptation of the present invention within the spirit of the present invention also belongs to the scope of the present invention and is not intended to limit the scope of the present invention.
[0034] The present invention provides a Staphylococcus aureus membrane vesicle encapsulated endoplasmic reticulum targeting nanoparticle (MVs@PLGA / TSE-PPA) for enhancing cancer immunotherapy. After the nanoparticles reach the tumor tissue, the bacterial membrane vesicles act as immune adjuvants to increase the proliferation of effector T cells in the tumor microenvironment. TSE-PPA can target the endoplasmic reticulum of tumor cells, causing immunogenic death of tumor cells, thereby synergistically enhancing cellular immune responses.
[0035] Omitted words:
[0036] MVs: Staphylococcus aureus membrane vesicles
[0037] TSE: N-Toluenesulfonylethylenediamine
[0038] PPA: Pyropheophorbide-a
[0039] DSPE-PEG2000: Phospholipid-polyethylene glycol 2000
[0040] PLGA: poly(lactic-co-glycolic acid)
[0041] HOBt: 1-Hydroxybenzotriazole
[0042] EDC: 1-ethyl-(3-dimethylaminopropyl)carbodiimide.
[0043] MPTP+: MVs@PLGA / TSE-PPA plus laser irradiation
[0044] PTP+: PLGA / TSE-PPA plus laser irradiation
[0045] PP+: PLGA / PPA plus laser irradiation
[0046] HEPES: 4-Hydroxyethylpiperazineethanesulfonic acid
[0047] Example 1 Extraction and purification of Staphylococcus aureus membrane vesicles MVs
[0048] The attenuated Staphylococcus aureus RN4220Δagr strain was revived and cultured on TSB solid plates for 24 hours, and a single colony was selected and cultured overnight in 10mL TSB medium at 37°C and 200rpm, and then transferred to 1L TSB liquid medium at a ratio of 1:100 and cultured at 37°C and 200rpm for 20 hours. After the culture, the bacterial culture medium was taken, centrifuged at 4°C for 20-30 minutes, the supernatant was collected, and filtered with a 0.45μm filter membrane to remove bacteria and bacterial debris. The filtrate was concentrated about 60 times by an ultrafiltration system with a molecular weight cutoff of 100kDa. The concentrate was filtered with a 0.22μm filter to remove any possible bacterial debris; the filtrate was centrifuged at 200000g for 3 hours at 4°C, and the precipitate was washed twice with sterile PBS. The precipitate was resuspended in 4.4 mL of 50% Optiprep buffer and transferred to an ultrafiltration tube. 4 mL of 40% and 1.6 mL of 10% Optiprep gradient buffer were carefully added to the upper layer of the ultrafiltration tube. The mixture was centrifuged horizontally at 200,000 g for 3 h at 4°C. The protein between the 40% and 10% interfaces was collected and dissolved in PBS. The MVs were stored at -80°C. The Optiprep buffer was prepared by dissolving 0.238 g of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) and 0.8775 g of NaCl in 100 mL of ddH2O, adjusting the pH to 7.0 with NaOH, filtering with a 0.22 um filter, and storing at room temperature.
[0049] Example 2 Preliminary evaluation of the safety and anti-tumor potential of MVs
[0050] Preliminary evaluation of the safety and anti-tumor potential of MVs prepared in Example 1
[0051] An orthotopic breast cancer model was established in BALB / C mice to evaluate the safety and antitumor effects of free MVs. The treatment process of tumor-bearing mice is shown in Figure 2 A.
[0052] 4T1 cells (1×10 7 ) was injected into the second fat pad of the right mammary gland of 8-week-old female BALB / C mice. The tumor volume grew to about 50-100 mm 3After 7 days (about 7 days), mice were intravenously injected with different doses of MVs, with three concentrations of low, medium and high (protein content was 10 μg for MVs-L, 25 μg for MVs-M and 50 μg for MVs-H, respectively). Blood samples were collected before and 1, 2, 3 and 4 days after MVs injection, and the immune responses of IL-6, IFN-γ and TNF-α were detected by enzyme-linked immunosorbent assay (ELISA). Tumor volume and mouse body weight were measured every day to analyze the anti-tumor potential of MVs. After treatment, blood samples were collected to evaluate blood biochemical parameters, including lactate dehydrogenase (LDH), creatine kinase (CK), urea (urea), creatinine (CREA), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Organs were collected for H&E staining.
[0053] The experimental results are as follows Figure 1 As shown, A is the experimental scheme of the anti-tumor effect of 4T1 tumor-bearing mice; B is the photo of 4T1 tumor-bearing mice after treatment; C is the curve of tumor volume change of mice after treatment with PBS and different concentrations of MVs; D is the tumor weight of mice at the end of the experiment; E is the spleen weight of mice at the end of the experiment; F is the body weight of mice during treatment; GI is the analysis of serum pro-inflammatory factors (IL-6, TNA-α and IFN-γ) levels; JO is the analysis of blood biochemical indicators (UREA, CREA, ALT, AST, CK, LDH) of tumor-bearing mice after MVs treatment.
[0054] Experimental results: The biosafety of MVs used in vivo has always been a focus of attention. MVs of Staphylococcus aureus usually carry some virulence-related factors, and removing the virulence in MVs is the primary task for the application of bacterial membrane vesicle products. The MVs of the present invention were prepared using the attenuated strain RN4220Δagr with agr knocked out, in which the auxiliary gene regulatory factor (agr) mainly upregulates the expression of bacterial virulence factors, and knocking it out can effectively reduce the virulence of MVs. The anti-tumor activity and biosafety of bacterial membrane vesicles (MVs) were then evaluated. It can be observed that different concentrations of MVs have an inhibitory effect on tumor growth (such as Figure 1 BD), there was no significant change in the spleen and body weight of mice (as shown in Figure 1 E and F). The results of proinflammatory cytokines showed that IFN-γ, TNF-α, and IL-6 increased on the first day after MV injection and began to drop to normal levels on the second day (as shown in Figure 2). Figure 1 GI). Blood biochemical parameters were measured to evaluate heart, kidney and liver function. The results showed that MVs had little effect on all blood biochemical parameters (such as Figure 1 The above results show that the bacterial membrane vesicles MVs prepared by the present invention can inhibit tumors within a certain concentration range and do not affect blood biochemical indicators, and can be further used in vivo.
[0055] Example 3 Preparation of MVs Nanoparticles MPTP
[0056] 1. Preparation of TSE-PPA
[0057] 120 mg TSE and 200 mg PPA were dissolved in 100 mL dichloromethane in a 250 ml round bottom flask, and then 143.9 mg EDC, 101 mg HOBt and 30 μL triethylamine were added as catalyst to synthesize TSE-PPA. After stirring for one day, the reaction solution was washed with 100 ml deionized water containing NaCl. The organic layer was purified by column chromatography on silica gel with a solvent (dichloromethane: ethyl acetate = 2:1), and the solvent was removed by rotary evaporation to obtain TSE-PPA.
[0058] 2. Preparation of PLGA / TSE-PPA (PTP)
[0059] 5 mg PLGA and 2.5 mg DSPE-PEG2000 were dissolved in 200 μL DMSO and mixed with 30 μL DMSO TSE-PPA solution at a concentration of 20 mg / mL, and then slowly added dropwise to 3 mL of deionized water with rapid stirring at room temperature to obtain a PTP nanoparticle solution.
[0060] 3. Preparation of MVs@PLGA / TSE-PPA (MPTP)
[0061] The prepared PLGA / TSE-PPA (PTP) nanoparticles were mixed with MVs and ultrasound for 2 min to obtain MVs@PLGA / TSE-PPA (MPTP) nanoparticles, that is, MVs encapsulated endoplasmic reticulum-targeted nanoparticles MPTP.
[0062] Example 4 MPTP Nanoparticle Characterization
[0063] The properties of the PTP and MPTP nanoparticles prepared in Example 3 were tested in a conventional manner using the following method.
[0064] Dynamic light scattering (DLS) instrument (Zeta sizer Nano ZS90, Malvern, UK) was used to measure the particle size and surface Zeta potential of PTP and MPTP nanoparticles.
[0065] Transmission electron microscopy (TEM) was used to obtain morphological images of PTP and MPTP nanoparticles. The composition of surface proteins of nanoparticles was analyzed by SDS-PAGE. The overlap of green fluorescence (DIO-labeled MVs) and red fluorescence (NPs) was observed by confocal microscopy to observe the successful encapsulation of bacterial membrane vesicles.
[0066] The ultraviolet absorption of the photosensitizer was measured using an ultraviolet spectrophotometer.
[0067] The DPBF probe was used to detect the generation of reactive oxygen species induced by MPTP nanoparticles, because reactive oxygen species can reduce the absorption of DPBF. DPBF was dissolved in DMF solution, and then 50 μL (1 mM) of DPBF was added to 3 mL of nanosolution. The mixture of DPBF and nanoparticles was then irradiated with a laser (1 W cm 687 nm), and its absorption spectrum was detected at different time points.
[0068] The experimental results are as follows Figure 2 As shown in the figure, A is a schematic diagram of MPTP preparation; B is a TEM image of PTP and MPTP nanoparticles; C is the particle size distribution of PTP and MPTP nanoparticles; D is the change in Zeta potential of PTP and MPTP nanoparticles in PBS (pH 7.4) at different time points; E is the change in particle size of PTP and MPTP nanoparticles in PBS (pH 7.4) at different time points; F is the composition of surface proteins of nanoparticles analyzed by SDS-PAGE; G is a confocal image of DIO-labeled MPTP nanoparticles; H is the ultraviolet absorption spectrum of MPTP nanoparticles; I is the ultraviolet absorption spectrum of a mixture of DPBF and MPTP nanoparticles under laser irradiation; J is the ratio of ultraviolet absorption to maximum absorbance at 420nm of a mixture of DPBF and MPTP nanoparticles at different time points.
[0069] Experimental results: Figure 2 As shown in A, the core of the endoplasmic reticulum (ER) targeted photodynamic therapy nanoparticles (NPs) was self-assembled by PLGA, TSE-PPA and DSPE-PEG2000 through nanoprecipitation. Transmission electron microscopy (TEM) showed that the surface of the nanoparticles was coated with a thin film, indicating that the bacterial vesicles MVs coated with PLGA / TSE-PPA nanoparticles were successfully prepared. The nanoparticle size was 100nm-150nm, with a narrow size distribution and a clear spherical morphology ( Figure 2 BC). After encapsulating MVs on the surface of nanoparticles, their size increased slightly. The changes in particle size and potential at different time points showed that PTP and MPTP particles remained stable in PBS solution for at least 24 h, showing excellent stability. The composition of proteins on the surface of nanoparticles was analyzed by SDS-PAGE. SDS-Page showed that the protein types expressed by MVs and MVs@PLGA / TSE-PPA were significantly the same ( Figure 2 F), indicating that PLGA / TSE-PPA nanoparticles were indeed encapsulated in MVs. In addition, Figure 2The green fluorescence (DIO-labeled MVs) and red fluorescence (NPs) in G clearly overlap, further indicating that MVs were successfully encapsulated on the surface of NPs. The UV absorption spectrum of NPs showed that the modification of TSE had little effect on the UV absorption of the photosensitizer ( Figure 2 H). The DPBF probe was used to detect the generation of reactive oxygen species induced by nanoparticles, because reactive oxygen species can reduce the absorption of DPBF. The results showed that under laser irradiation, the UV absorption spectrum of DPBF decreased rapidly, proving that MPTP produces ROS under laser irradiation. The control experimental groups included blank nanoparticles + DPBF, blank nanoparticles + DPBF + laser, and DPBF + laser. No significant changes were observed in the UV absorption spectrum of the control group ( Figure 2 IJ).
[0070] Example 5 MPTP activity experiment
[0071] 1. In vitro endoplasmic reticulum targeting experiment of MPTP
[0072] ER targeting experimental method: First, 4T1 cells were seeded on the cover of a 12-well plate (5×10 4 After incubation with PTP and MPTP (equivalent to 10 μg / mL PPA) for 4 h, the cells were washed with PBS and then incubated with 75 nM ER-TrackerGreen at 37 °C for 30 min. After incubation, the cells were washed with PBS, fixed with 4% paraformaldehyde for 20 min, and then stained with 5 mg / mL DAPI for 5 min. Finally, the colocalization of nanoparticles and endoplasmic reticulum was observed using a confocal microscope.
[0073] 2. Evaluation of MPTP nanoparticle-induced ROS generation
[0074] Flow cytometry and confocal microscopy were used to quantitatively and qualitatively study the ROS generation of 4T1 cells. 5 Each well of a 12-well plate was inoculated and cultured for 24 h. Then, the cells were incubated with PP, PTP, and MPTP (equivalent to 10 μg / mL PPA) for 4 h. After incubation, each well was irradiated with laser for 3 min (687 nm, 1 W / cm 2 ), continue to culture for 4 hours, wash the cells with PBS, incubate with 10μM / L DCFH-DA for 30 minutes, wash with PBS, collect the cells, and analyze the fluorescence intensity by flow cytometry. The steps of quantitative analysis were consistent. After incubation with 10μM / L DCFH-DA for 30 minutes, wash the cells with PBS, fix with 4% paraformaldehyde for 20 minutes, and then stain with 5mg / mL DAPI for 5 minutes, and finally perform microscopy imaging.
[0075] The experimental results are as follows Figure 3As shown, A is the confocal image of 4T1 cells treated with PTP and MPTP nanoparticles, showing the ER co-localization of PPA and TSE-PPA; BC are linear scanning fluorescence intensity spectra showing the ER co-localization of PPA and TSE-PPA nanoparticles; D is the confocal image of ROS expression in 4T1 cells after treatment with different treatment groups; EF are the average fluorescence intensities of ROS expression in 4T1 cells after treatment with different treatment groups detected by flow cytometry.
[0076] Experimental results: Figure 3 A shows the colocalization of nanoparticles and the endoplasmic reticulum, which was stained with ER-Tracker Green. The overlap of the red fluorescence of the nanoparticles (NPs) and the green fluorescence (endoplasmic reticulum) shows that PTP aggregates more in the endoplasmic reticulum than PP, indicating that PTP can be targeted to the endoplasmic reticulum through TSE modification. The linear scanning fluorescence intensity spectrum further confirms this result ( Figure 3 BC). Photodynamic therapy kills tumors mainly by inducing the production of therapeutic ROS. To further study the ability of MPTP to produce ROS, we used DCFH-DA fluorescent dye to study the level of ROS produced by nanoparticles-induced cells. Figure 3 As shown in D, compared with the PBS group, the PP, PTP, and MPTP groups induced a large amount of ROS generation under laser stimulation, and the MPTP group also enhanced ROS generation. Flow cytometry and quantitative results showed that MPTP+ treatment produced the most significant ROS in 4T1 tumor cells ( Figure 3 E-3F), which may be a synergistic effect of photodynamic therapy combined with stimulation of bacterial membrane vesicles.
[0077] 3. Evaluation of MPTP nanoparticle-induced 4T1 cell immune death
[0078] Immunofluorescence was used to observe the effects of nanoparticles on CRT exposure and HMGB1 extracellular release. First, 4T1 cells were seeded on the coverslip of a 12-well plate (5×10 4 After 24 h of culture, the cells were incubated with PP, PTP, and MPTP (10 μg / mL PPA equivalent) nanoparticles for 4 h. After incubation, the laser treatment group was irradiated with laser for 3 min (687 nm, 1 W / cm 2 ), continue to culture for 4 hours, wash the cells with PBS, fix them with 4% paraformaldehyde for 20 minutes, and then incubate them with anti-CRT antibody / HMGB1 antibody (2.5μg / mL) overnight. After incubation, incubate the cells with fluorescent secondary antibody, wash with PBS, stain with 5mg / mL DAPI for 5 minutes, and finally observe the fluorescence with confocal microscope.
[0079] To investigate the secretion of extracellular ATP and HMGB1, 4T1 cells were seeded in 12-well plates and treated with PP, PTP, and MPTP (10 μg / mL PPA equivalent) for 4 h. After incubation, the laser treatment group was irradiated with laser for 3 min (687 nm, 1 W / cm 2 ), and the culture was continued for 4 h. The concentrations of ATP and HMGB1 in the collected supernatant were determined using ATP Assay Kit and HMGB1 ELISA kit.
[0080] 4. In vitro maturation of BMDCs
[0081] To evaluate whether MPTP can activate immune response, immune cells were analyzed by flow cytometry. First, the maturation of dendritic cells was evaluated because it is required for immune activation. Mouse tibia and femur bone marrow cells were collected and cultured with GM-CSF (20 ng / mL) and IL-4 (10 ng / mL) for 7 days to obtain mouse bone marrow dendritic cells (BMDC). The Transwells method was used to evaluate the maturation of BMDCs. 1×10 4T1 cells were placed in the 4T1 cells. 5 The cells were inoculated into the wells of the Transwell plate incubated with PP, PTP, and MPTP (10 μg / mL PPA equivalent) for 4 h, and then irradiated with laser for 3 min (687 nm, 1 W / cm 2 BMDCs were seeded in the lower chamber of the Transwell plate and co-cultured with pretreated 4T1 cells for 24 h. The cells in the lower chamber were collected and stained with anti-CD45-APC750, anti-CD11c-PEcy7, anti-CD80-FITC, and anti-CD86-BV421, and finally evaluated by flow cytometry.
[0082] The experimental results are as follows Figure 4 As shown, AB are the confocal images of CRT and HMGB1 expression in 4T1 cells after treatment with different treatment groups; CD are the average fluorescence intensities of CRT and HMGB1 expression in 4T1 cells after treatment with different treatment groups; E is the result of enzyme-linked immunosorbent assay of HMGB1 in 4T1 cells after treatment with different treatment groups; F is the ATP secretion of 4T1 cells after treatment with different treatment groups measured by ATP assay kit; GH are the co-culture of tumor cells after photodynamic therapy with DC cells to study the stimulating effect on DC maturation.
[0083] Experimental results: When immunogenic death occurs, it will cause the exposure of calreticulin (CRT), the release of high-mobility group protein (HMGB1) and ATP. The effects of nanoparticles on these three indicators were detected to investigate whether MPTP can enhance the induction of ICD. Figure 4As shown in A, compared with the PBS group, the PP+, PTP+, and MPTP+ groups showed more green fluorescence on the surface of 4T1 cells, indicating more CRT exposure on the surface of 4T1 cells, proving that photodynamic therapy can cause immunogenic death. The PTP+MPTP+ group showed stronger CRT exposure than the PP+ group, indicating that endoplasmic reticulum stress with enhanced ER targeting ability can indeed induce stronger ICD. Semi-quantitative results showed that the MPTP+ group produced greater CRT exposure than the PTP+ and PP+ groups (e.g. Figure 4 C). Figure 4 B is the distribution of HMGB1 in 4T1 cells after treatment with nanoparticles such as MPTP. HMGB1 in the PBS and MPTP groups was mainly located in the cell nucleus, while most of the HMGB1 in the PP+, PTP+ and MPTP groups was released from the cell nucleus, and the green fluorescence in the cell nucleus was weakened. Semi-quantitative analysis also showed this result ( Figure 4 D). Further Elisa detection of HMGB1 release in cell culture medium showed that the release of HMGB1 in MPTP+, PTP+, PP+ and MPTP groups was 7.2, 5.3, 3.8 and 2.4 times higher than that in PBS group, respectively (e.g. Figure 4 E). Figure 4 F is the effect of nanoparticles on ATP release. All treatment groups significantly increased ATP release. To further investigate whether enhanced ICD would lead to BMDCs maturation, BMDCs were co-cultured with 4T1 cells pretreated with nanoparticles such as MPTP using a Transwells assay. Figure 4 As shown in G-4H, after 24h of incubation with MPTP+, the BMDCs maturation rate was the highest, reaching 42.8%. The above results suggest that ROS can induce immunogenic cell death (ICD), and ER targeting can enhance ER stress and increase the release of immunostimulatory signals. It is worth noting that bacterial vesicles can also stimulate the production of ROS to activate immunogenic death, so the MPTP+ group induced the strongest immunogenic death.
[0084] 5. In vivo anti-tumor and ICD observation
[0085] An orthotopic breast cancer model was established in BALB / C mice to evaluate the antitumor effect of nanoparticles. 7 4T1 cells were injected into the second fat pad of the right mammary gland of 8-week-old female BALB / C mice. 3(about 7 days), they were randomly divided into 5 groups and intravenously injected with PBS, PP, PTP, and MPTP (PPA: 5 mg / kg). After 24 hours, the tumor site was laser irradiated for 5 minutes, and 2 rounds of treatment were continued. At the same time, the tumor volume and body weight of the mice were monitored every 2 days. Tumor volume = long diameter × short diameter × short diameter / 2. The formula for calculating the tumor inhibition rate is: tumor inhibition rate = (tumor volume in the PBS group - tumor volume in the experimental group) / tumor volume in the PBS group × 100%. After the experiment, organs, tumor tissues, and lymph nodes were collected. One tumor tissue section was stained, and tumor sections stained with hematoxylin and eosin (H&E) were used to evaluate tumor cell death, and tumor sections stained with ICD markers (CRT and HMGB1) were used to evaluate in vivo ICD. The remaining tumor tissues and lymph nodes were detected by flow cytometry for immune cells.
[0086] The experimental results are as follows Figure 5 As shown, A is the experimental scheme of the anti-tumor effect of 4T1 tumor-bearing mice; B is the tumor growth curve of mice after treatment with PBS, PP+, PTP+, MPTP+, and MPTP; C is the tumor weight of mice at the end of the experiment; D is the weight change curve of mice after treatment with PBS, PP+, PTP+, MPTP+, and MPTP; E is the obtained tumor tissue H&E staining, CRT exposure, and HMGB1 release in tumor sections.
[0087] Experimental results: Figure 5 A anti-tumor experiment, tumor growth curve and tumor weight showed that compared with the control group and MPTP group, the tumor was significantly inhibited after PP+laser, PTP+laser, and MPTP+laser treatment ( Figure 5 B-5C), among which the MPTP+laser group had the best anti-tumor effect, which may be related to the combination of endoplasmic reticulum-targeted photodynamic therapy and bacterial vesicle immunotherapy. Each treatment group had no effect on the weight of mice ( Figure 5 D) Tumor sections were further stained with hematoxylin and eosin (H&E) to observe the anti-proliferative effect of nanoparticles. Dense nucleated cells were observed in both PBS and MPTP groups. Dense nucleated cells were significantly reduced in PP+laser group, PTP+laser group, and MPTP+laser group, and sparse apoptotic areas increased, especially in MPTP+laser group, where the number of cell nuclei was the least ( Figure 5 E). To evaluate whether ER-targeted photodynamic therapy can enhance ICD-induced immune responses in vivo, we further investigated the expression of CRT and HMGB1 in tumor sections. MPTP+ laser-induced CRT irradiation was the highest, with obvious green fluorescence in cells and significant nuclear release of HMGB1 ( Figure 5 E), indicating that ER-targeted photodynamic therapy combined with bacterial membrane vesicles enhanced ICD in tumor tissues.
[0088] 6. Investigation of in vivo immune effects
[0089] Tumors and lymph nodes collected from animal experiments were ground and filtered to prepare single cell suspensions. Lymph node cells were used for DC analysis, and cells were stained with anti-CD45-APC750, anti-CD11c-PEcy7, anti-CD80-FITC and anti-CD86-BV421 for flow cytometry evaluation. Tumor tissue cells were centrifuged with 40% / 70% percoll to obtain immune cells, which were stained with anti-CD3-PC5.5, anti-CD4-FITC, anti-CD8-PEcy7, anti-IFN-γ-APC and anti-TNF-α-PE to analyze the infiltration of functional CD8+T cells and CD4+T cells in the tumor.
[0090] The experimental results are as follows Figure 6 As shown in the figure, A and B are the proportions of mature DC cells in lymph node tissue after treatment; C and E are the proportions of CD8 + T cell infiltration; D and F are CD4 + T cell infiltration; G is IFN-γ in the tumor after treatment + CD8 + T cell infiltration; H is intratumoral TNF-α + CD8 + T cell infiltration; I is tissue section to examine CD4 + T cells and CD8 + T cells.
[0091] Experimental results: Flow cytometry was used to detect mature DC cells (CD11c+CD45+CD80+CD86+) in the tumor-draining lymph nodes. The number of mature DC cells in the PP+, PTP+, MPTP+, and MPTP groups was 4.66, 6.01, 7.8, and 2.11 times that of the PBS group, respectively. Figure 6 A-6B), the results showed that each treatment group could significantly induce DC maturation in vivo, and mature DC cells could stimulate T cell activation to produce immune response. The infiltration of functional CD8+T cells and CD4+T cells in the tumor was further studied. The tumor-infiltrating CD4+ and CD8+ cytotoxic T lymphocytes in the PP+, PTP+, and MPTP+ treatment groups increased significantly. It is worth noting that the infiltration rate of CD4+ and CD8+T cells in the MPTP+ group was higher than that in the other groups ( Figure 6 CF). Similarly, the percentages of IFN-γ+CD8+T cells and TNF-α+CD8+T cells in the tumors of the MPTP+ treatment group were increased compared with those of the PBS or other groups ( Figure 6 GH). Immunofluorescence was further used to detect the content of CD4+ and CD8+ T cells in tumor tissues. MPTP+laser induced the highest infiltration of CD8+ T cells and CD4+ T cells, accompanied by obvious red fluorescence ( Figure 6 I). These results suggest that ER-targeted photodynamic therapy combined with bacterial membrane vesicles produced a strong immune response in vivo.
[0092] 7. Anti-metastatic effect of MPTP on 4T1 tumor-bearing mice with lung metastasis
[0093] A 4T1 tumor model with lung metastasis was established to investigate whether MPTP+ could inhibit tumor metastasis. 7 4T1 cells were injected into the second fat pad of the right mammary gland of 8-week-old female BALB / C mice. 3 After about 7 days, 1×10 7 4T1 cells were randomly divided into 5 groups and intravenously injected with PBS, PP, PTP, and MPTP (PPA: 5 mg / kg). After 24 hours, the laser treatment group irradiated the tumor site with laser for 5 minutes and continued 2 rounds of treatment. The weight of the mice was monitored. After 2 weeks, the lung tissues were collected by dissection, photographed and weighed, and HE staining was performed.
[0094] The experimental results are as follows Figure 7 As shown in the figure, A is the anti-metastasis experimental plan of 4T1 tumor-bearing mice with lung metastasis; B is a picture of lung tissue; C is a microscope image of lung tissue after H&E staining, scale: 250μm; D is the weight of lung tissue; E is the inhibition rate of lung metastasis of mice after treatment with PBS, PP+laser, PTP+laser, MPTP+laser, and MPTP; F is the weight change curve of mice after treatment with PBS, PP+laser, PTP+laser, MPTP+laser, and MPTP.
[0095] Experimental results: Figure 7 A Anti-metastasis experiment, a large number of lung metastatic nodules were clearly visible in the PBS group, while the lung metastatic nodules in the PP+laser, PTP+laser, MPTP+laser, and MPTP treatment groups were significantly reduced, especially the MPTP+laser treatment group had the least lung metastatic nodules ( Figure 7 B). HE staining of lung tissue showed that the PBS group had dense tumor cells, followed by the MPTP+ group, PP+ group and PTP+ group. There were almost no tumor cells in the MPTP group ( Figure 7 C). The increase in lung metastasis nodules will cause an increase in lung tissue weight. The lung weight results also showed that MPTP+ laser had the best anti-lung metastasis effect in each group, with the highest inhibition rate, followed by PTP+ and PP+ ( Figure 7 D-7E). In addition, all treatments did not cause significant changes in body weight, indicating that they have good biosafety ( Figure 7 F). The experimental results show that MPTP+laser has a significant effect in inhibiting tumor metastasis.
Claims
1. A Staphylococcus aureus membrane vesicle encapsulated endoplasmic reticulum targeting nanoparticle, comprising Staphylococcus aureus membrane vesicles (MVs), PLGA, DSPE-PEG2000 and N-tosylethylenediamine (TSE)-modified pyropheophorbide-a (PPA) (TSE-PPA), wherein: The TSE-PPA forms nanoparticles with PLGA and DSPE-PEG2000, and the nanoparticles are then encapsulated in MVs to form MVs@PLGA / TSE-PPA nanoparticles.
2. The nanoparticles according to claim 1, wherein the mass ratio of TSE to PPA in the TSE-PPA is 3:
5.
3. The nanoparticles as claimed in claim 1, wherein the mass ratio of PLGA to TSE-PPA is 25:3; and the mass ratio of PLGA to DSPE-PEG2000 is 2:
1.
4. A method for preparing the endoplasmic reticulum-targeted nanoparticles according to any one of claims 1 to 3, comprising the following steps: 1) Dissolve TSE and PPA in dichloromethane, add catalyst EDC, HOBt and triethylamine to react and generate TSE-PPA; 2) dissolving PLGA and DSPE-PEG2000 in DMSO, adding TSE-PPA DMSO solution, mixing, stirring, and slowly adding deionized water dropwise to obtain PLGA / TSE-PPA nanoparticle solution; 3) The PLGA / TSE-PPA nanoparticle solution obtained in the previous step is ultrasonically mixed with MVs to obtain MVs@PLGA / TSE-PPA nanoparticles.
5. The preparation method according to claim 4, in step 1), further comprising washing the generated TSE-PPA solution with deionized water containing NaCl, purifying the organic layer by column chromatography, and evaporating to obtain TSE-PPA.
6. The preparation method according to claim 5, wherein the mobile phase of the column chromatography purification is a mixture of dichloromethane:ethyl acetate = 2:
1.
7. The preparation method according to claim 4, wherein in step 1), the mass volume ratio of EDC, HOBt and triethylamine is 144 mg: 101 mg: 30 μL, wherein: The mass ratio of PPA to HOBt is (1.9-2.0):
1.
8. The preparation method according to claim 4, wherein the DMSO solution of TSE-PPA has a TSE-PPA concentration of 20 mg / mL.
9. The preparation method according to claim 4, wherein the MVs in step 3) are prepared by the following method: a. Resuscitate the attenuated Staphylococcus aureus RN4220Δagr for 24 hours, select a single colony, shake culture it in TSB medium at 37°C and 200 rpm overnight, transfer it to 1L TSB liquid medium at a ratio of 1:100, shake culture it at 37°C and 200 rpm for 20 hours, and obtain a bacterial culture medium; b. Take the bacterial culture medium, centrifuge it at 4°C for 20-30 minutes, collect the supernatant, filter it with a 0.45μm filter membrane to remove bacteria and bacterial debris, and use an ultrafiltration system with a molecular weight cutoff of 100kDa to concentrate the filtrate by about 60 times. Filter the concentrate with a 0.22μm filter, centrifuge the filtrate at 200000g at 4°C for 3 hours, and take the precipitate; c. Wash the precipitate twice with sterile PBS, resuspend the precipitate in 4.4 mL 50% Optiprep buffer, transfer it to an ultrafiltration tube, add 4 mL 40% and 1.6 mL 10% Optiprep gradient buffer to the upper layer of the ultrafiltration tube, centrifuge horizontally at 200,000 g for 3 h at 4°C, collect the protein between the 40% and 10% interfaces, dissolve it in PBS, and store it at -80°C to obtain MVs; in, Preparation of Optiprep buffer: Dissolve 0.238 g of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) and 0.8775 g of NaCl in 100 mL of ddH2O, adjust the pH to 7.0 with NaOH, and filter through a 0.22 um filter.
10. Use of the Staphylococcus aureus vesicle-encapsulated endoplasmic reticulum-targeted nanoparticles according to claims 1-3 in the preparation of drugs or agents for treating tumors.
